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Despite increased use of insulin pumps, many youth with
T1D exhibit significant glycemic variability (GV). Emerging
data suggest that GV relates to complications of diabetes.1,2
Prior studies demonstrated that entering self-monitoring
blood glucose (SMBG) and carbohydrate data into the pump
and delivering insulin boluses relate to improved mean
blood glucose (BG) and glycated hemoglobin (HbA1c).3,4
We hypothesized that as patients increased these behaviors,
GV would decrease.
Average daily risk range (ADRR) measures GV and is
calculated from SMBG data using days with ⩾3 SMBG; a
minimum of 14 days is required. It is computed by mathematically transforming BGs into a symmetrical scale giving
equal weight to hyperglycemic and hypoglycemic values and
computing the mean of daily high and low values. Higher
values suggest risk of hyperglycemia and hypoglycemia.5
Multiplicative standard deviation (MSD) similarly corrects
for skewed data distributions. Logarithmic transformation of
BGs yields a symmetrical distributional form; SD is then calculated on log-transformed values, and the result is exponentiated, which yields the nonscalar MSD parameter.6 For
example, for a set of BGs with an MSD of 1.5 and an average
of 150 mg/dL, the values 225 mg/dL and 100 mg/dL are 1
MSD above and below the mean, respectively, reflecting the
asymmetry of the BG data. We evaluated pump data on a
random sample of 100 patients with T1D aged 3.5-20.5 years
(median 15.0 years). Associations between adherence behaviors and GV were evaluated using Spearman correlations
with P < .05 as significant.
Patients entered SMBG ⩾4 times on 52% of study days,
carbohydrates ⩾3 times on 71% of study days, and delivered boluses ⩾3 times on 80% of study days. HbA1c was
inversely correlated with number of days entering SMBG
⩾4 (rho = −.342, P < .001), carbohydrates ⩾3 (rho =
−.382, P < .001), boluses ⩾3 (rho = −.316, P = .001), and
completing all three behaviors (rho = −.374, P < .001).
HbA1c was positively correlated with number of days with

Table 1. Spearman Correlations.
Variable

MSD

P value

ADRR

P value

HbA1c
Age
Days bolus ⩾ 3
Days carb entry ⩾ 3
Days SMBG ⩾ 4
Gave > rec bolus
Gave < rec bolus
Days no bolus
Days no SMBG
Days with BG, bolus, carb

.272
−.086
−.053
−.160
−.007
.169
.088
.131
−.035
−.063

.006
.398
.598
.113
.947
.093
.387
.192
.729
.535

.409
−.390
.114
−.062
.357
.060
.031
−.085
−.302
.223

<.0001
<.0001
.260
.539
.0003
.554
.759
.403
.002
.026

no bolus (rho = .234, P = .019), no SMBG (rho = .369,
P = .0002), and number of times the patient gave less insulin than recommended by the bolus advisor (rho = .382,
P < .0001). HbA1c was positively correlated with MSD
(rho = .272, P = .006) and ADRR (rho = .409, P < .001).
Increased adherence behaviors were not significantly correlated with decreased GV (Table 1). Entering SMBG ⩾4, carbohydrates ⩾3, or bolus delivery ⩾3 times per day were not
correlated with MSD. Entering carbohydrate or bolus ⩾3 times
per day did not relate to ADRR. ADRR was positively correlated with number of days with SMBG entries ⩾4, days with no
SMBG, and days all three behaviors occurred. The direction of
these correlations was unexpected. We hypothesized that more
frequent behaviors would relate to lower ADRR. This paradox
might be explained by the method of ADRR calculation relying
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on maximum and minimum BGs. As BG checks increase, there
are more opportunities to capture extreme out-of-target BGs,
yielding a higher ADRR. Similarly, increased engagement with
SMBG and carbohydrate entry may yield more boluses, which
could lead to more GV.
We did not find an association between pump adherence
behaviors and GV. Additional behaviors should be considered as targets for interventions to decrease GV, and other
measures of GV deserve further study.
Abbreviations
ADRR, average daily risk range; BG, blood glucose, GV, glycemic
variability; HbA1c, glycated hemoglobin; MSD, multiplicative
standard deviation; SD, standard deviation; SMBG, self-monitoring
blood glucose; T1D, type 1 diabetes.
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